Stockholm, Sweden — Medivir AB (Nasdaq Stockholm: MVIR) today announced that the number of shares and votes in Medivir has changed as a result of redemption of share under the voluntary redemption programme resolved at the extraordinary general meeting on 20 November 2014. The new number of shares has been registered with the Swedish Companies Registration Office during March 2015.
Today, the last trading day of the month, the total number of outstanding shares in Medivir are 26,966,037, whereof 606,358 series A shares and 26,359,679 series B shares, and the total number of votes amounts to 32,423,259 votes.
For further information, please contact:
Ola Burmark, CFO Medivir AB, mobil: +46 (0)725-480 580.
Medivir is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 8.30 CET on 31 March 2015.
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market. Medivir is listed on the Nasdaq Stockholm Mid Cap List.